Light & Wonder, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Light & Wonder, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $823.00M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $768.90M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $766.30M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $725.40M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $752.20M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $720.00M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $729.20M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $682.00M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $737.00M | Mar 3, 2017 |
| FY2016 | Sep 30, 2015 | $671.60M | Mar 3, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.31B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.19B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $2.90B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $2.51B | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $580.00M | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | $539.00M | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $581.00M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | $453.00M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $480.00M | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | $432.00M | Mar 1, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $276.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $336.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $163.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $3.68B | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $95.00M | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | $182.00M | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $109.00M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | ($15.00M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | ($90.00M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | ($117.00M) | Mar 1, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $683.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $668.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $518.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $273.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $110.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($245.00M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $290.00M | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | $321.20M | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | ($204.50M) | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | $99.50M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $252.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $262.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $228.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $218.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $190.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $148.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $166.00M | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | $49.80M | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | $49.50M | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | $49.20M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $869.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $872.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $808.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $717.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $679.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $627.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $619.00M | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | $181.70M | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | $169.70M | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | $173.90M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $794.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $632.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $590.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($381.00M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $685.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $471.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $546.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $346.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $507.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $419.00M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $200.40M | Feb 29, 2016 |
| FY2015 | Dec 31, 2014 | $107.50M | Feb 29, 2016 |
| FY2015 | Dec 31, 2013 | $84.30M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $44.80M | Mar 17, 2015 |
| FY2013 | Dec 31, 2011 | $43.40M | Mar 17, 2014 |
| FY2012 | Dec 31, 2010 | $62.93M | Mar 12, 2013 |
| FY2011 | Dec 31, 2009 | $64.61M | Feb 29, 2012 |
| FY2010 | Dec 31, 2008 | $163.95M | Mar 1, 2011 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.46B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $5.42B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.55B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $6.01B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $7.88B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $7.98B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $7.81B | Mar 1, 2021 |
| FY2020 | Dec 31, 2018 | $7.72B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $7.73B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $7.09B | Feb 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.22B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.79B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $4.79B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $4.85B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $9.99B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $10.51B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $9.92B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $10.18B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $9.75B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $9.02B | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $765.00M | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | $990.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($2.26B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($2.65B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($2.21B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($2.46B) | Feb 18, 2020 |
| FY2019 | Dec 31, 2017 | ($2.03B) | Feb 18, 2020 |
| FY2019 | Dec 31, 2016 | ($1.94B) | Feb 18, 2020 |
| FY2017 | Dec 31, 2015 | ($1.50B) | Mar 1, 2018 |
| FY2015 | Sep 30, 2015 | ($1.38B) | Feb 29, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.37B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.89B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $2.95B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $2.92B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $2.89B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $2.73B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $2.73B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $3.28B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $2.96B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $2.89B | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $680.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $517.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($3.16B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($3.53B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($2.95B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($2.82B) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($2.46B) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($2.22B) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $196.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $425.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $914.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $585.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $928.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $313.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $168.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $788.80M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $115.10M | Mar 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 38 | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | 1 | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | (1) | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 38 | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | 1 | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | (1) | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 77.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 86.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 90.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 91.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 97.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 95.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 94.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 92.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | 90.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | 88.00M | Feb 28, 2019 |